Synthetic cannabinoid Dexanabinol not effective

Pharmos Corporation announced on 20 December results of its phase III clinical study of dexanabinol to treat severe traumatic brain injury. Dexanabinol is a neuroprotecting synthetic cannabinoid.
However, it did not demonstrate efficacy as measured by the primary clinical outcome endpoint, the Extended Glasgow Outcome Scale (GOSE). The placebo-controlled trial was conducted in 86 trauma centres in 15. 846 patients were available for analysis, 428 treated with dexanabinol and 418 treated with placebo.
While efficacy was not established, the trial demonstrated an excellent safety profile for dexanabinol. There were also no differences in mortality between the two groups.